Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels

December 15, 2023

https://www.globenewswire.com/news-release/2023/12/04/2790002/0/en/Viracta-Therapeutics-Announces-Interim-Data-from-Phase-1b-2-Clinical-Trial-of-Nana-val-in-Patients-with-Epstein-Barr-Virus-Positive-Solid-Tumors-that-Show-Confirmed-Tumor-Responses.html

Confirmed partial responses without dose-limiting toxicities during dose escalation along with new preclinical data support the opportunity to further enhance efficacy through a novel split daily dosing regimen at higher dose levels of Nana-val

Read more at globenewswire.com

Related news for (VIRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.